drugset / Trial / NCT00168753
Community Based Trial for AMEVIVE®
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the safety of treating subjects with up to 12 additional doses of alefacept.
Timeline
- Start
- 2004-07
- Primary completion
- 2005-03
- Completion
- 2005-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alefacept | Protein / enzyme biologic | 15 mg | Intramuscular |